NasdaqCM:CBLI

Stock Analysis Report

Executive Summary

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Cleveland BioLabs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBLI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.6%

CBLI

-1.5%

US Biotechs

-4.2%

US Market


1 Year Return

81.6%

CBLI

10.2%

US Biotechs

14.0%

US Market

Return vs Industry: CBLI exceeded the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: CBLI exceeded the US Market which returned 14% over the past year.


Shareholder returns

CBLIIndustryMarket
7 Day7.6%-1.5%-4.2%
30 Day72.0%3.9%-1.8%
90 Day159.2%3.4%2.6%
1 Year81.6%81.6%11.1%10.2%16.3%14.0%
3 Year33.5%33.5%19.6%16.4%43.2%34.0%
5 Year-36.8%-36.8%1.3%-3.4%65.9%47.6%

Price Volatility Vs. Market

How volatile is Cleveland BioLabs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cleveland BioLabs undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cleveland BioLabs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cleveland BioLabs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Cleveland BioLabs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cleveland BioLabs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cleveland BioLabs performed over the past 5 years?

-1.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CBLI is currently unprofitable.

Growing Profit Margin: CBLI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CBLI is unprofitable, and losses have increased over the past 5 years at a rate of -1.8% per year.

Accelerating Growth: Unable to compare CBLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: CBLI has a negative Return on Equity (-146.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cleveland BioLabs's financial position?


Financial Position Analysis

Short Term Liabilities: CBLI's short term assets ($2.2M) exceed its short term liabilities ($565.7K).

Long Term Liabilities: CBLI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CBLI is debt free.

Reducing Debt: CBLI has no debt compared to 5 years ago when its debt to equity ratio was 127.6%.


Balance Sheet

Inventory Level: CBLI has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CBLI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBLI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CBLI has less than a year of cash runway if free cash flow continues to grow at historical rates of 30.9% each year.


Next Steps

Dividend

What is Cleveland BioLabs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CBLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CBLI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Christopher Zosh (44yo)

0.2yrs

Tenure

0

Mr. Christopher Zosh serves as Interim Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at Cleveland BioLabs, Inc. since December 13, 2019. Mr. Zosh has served as V ...


Leadership Team

NamePositionTenureCompensationOwnership
Langdon Miller
President & Chief Medical Officer4.8yrsUS$119.55kno data
Andrei Gudkov
Chief Scientific Officer16.7yrsUS$110.94k0.67% $172.2k
Christopher Zosh
VP of Finance0.2yrsno datano data
Ann Hards
Executive Vice President of Regulatory Affairs0yrsno datano data

4.8yrs

Average Tenure

63yo

Average Age

Experienced Management: CBLI's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Randy Saluck
Independent Director3.6yrsUS$35.00k0.0012% $318.0
Anna Evdokimova
Independent Director4.6yrsno datano data
Daniil Talyanskiy
Independent Director3.6yrsno datano data
Lea Verny
Chair of the Board3.6yrsUS$35.00kno data
Alexander Andryuschechkin
Independent Director3.6yrsno datano data
Ivan Fedyunin
Independent Director1.5yrsno datano data

3.6yrs

Average Tenure

39yo

Average Age

Experienced Board: CBLI's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cleveland BioLabs, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cleveland BioLabs, Inc.
  • Ticker: CBLI
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$25.647m
  • Shares outstanding: 11.30m
  • Website: https://www.cbiolabs.com

Number of Employees


Location

  • Cleveland BioLabs, Inc.
  • 73 High Street
  • Buffalo
  • New York
  • 14203
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2006
7CB1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2006

Biography

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company’s product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 00:56
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.